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Introduction. Seizures can be due to a variety of 
acute, subacute, or chronic diseases with different 
etiologies. Clinically, they may manifest as focal or 
generalized phenomena (Table I). Whereas the ma-
jority of the patients suffering from partial seizures 
are easily controlled with medications, in a small 
number of patients treatment may fail. The failure 
may be due to incorrect diagnosis or incorrect 
therapy. The efficacy of medical treatment for seizure 
disorder depends upon six factors: I) dosage; 2) the 
size of the patient; 3) drug interaction; 4) drug 
specificity for the disease; 5) the nature of the disease 
for which the drug is used; 6) the mode and frequency 
of medication. 
Dosage of Anticonvulsant. The dosage of anti-
convulsant is very important (Table 2) . In our ex-
perience, the most common cause of failure in treat-
ment of seizure disorders is undermedication. It is 
also well known that the anticonvulsants in large 
enough dos~s can act as convulsants. This is espe-
cially true for diphenylhydantoin, benzodiazepines, 
and lidocaine. An important factor in dosage of drug 
is patient reliability. Measurement of blood levels of 
anticonvulsant can be helpful in this respect (Table 3). 
Size of the Patient. The size of the patient 
should be considered in dosage. Measurement accord-
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ing to body surface is safer and more accurate 
(Table 2). As the child grows, there may be a need to 
gradually increase the dose of anticonvulsants if 
seizure control is poor or if the serum level of the an-
ticonvulsant starts to decline. 
Drug Interaction. The relationship of multiple 
drug therapy to its toxic effects on the brain is quite 
complicated, and many forms of therapeutic failure 
or toxicity can result. 
Combination of Similar Drugs. Failure or toxicity 
may be the result of a combination of phar-
macologically similar drugs. Such a combination may 
enhance the side effects of drowsiness and ataxia. The 
patient may suffer from these side effects without at-
taining therapeutic levels of individual anticon-
vulsants in the blood. For example, a combination of 
dn1gs such as phenobarbital and primidone may 
result in severe ataxia and drowsiness while measure-
ment of serum levels of phenobarbital and primidone 
in such patients may show subtherapeutic levels. 
The combination of the following phar-
macologically similar drugs should be avoided: I) 
phenobarbital and primidone, mephobarbital 
(Mebaral®), and metharbital (Gemonil®); 2) etho-
suximide and methsuximide; 3) diphenylhydantoin 
(DPH) and mephenytoin; 4) trimethadione and 
paramethadione; 5) benzodiazepines (e.g., combina-
tion of diazepam, clonazepam (Clonapin®), chlor-
diazepoxide); 6) phenobarbital and ethanol; 7) 
phenobarbital and benzodiazepines. 
Combination of Inducers of Drug Metabolism . 
This combination may result in less effective 
MCV QUARTERLY 10(4): 208-219, 1974 
HOOSHMAND: INTRACTABLE PARTIAL COMPLEX SEIZURES 209 
TABLE 1 
A Simple Classification of Seizure Disorders• 
I. Focal (partial) 
a. cortical 
b. subcortical 
c. both cortical and subcortical 
2. Generalized 
a. low threshold (e.g. drug withdrawal, toxic-metabolic, 
benign febrile seizures) 
b. secondary to focal 
• Any of the above may be clinical or subclinical (EEG 
manifestation). 
therapeutic doses of each drug in the blood, and less 
effective control of seizures, despite toxic side effects. 
Whereas the failure may be due to genetic, phar-
macological or physiological factors which alter ab-
sorption metabolism or excretion of the drug, or the 
failure may be due to compliance behavior of the 
patient or to lack of drug specificity for the disease, 
the clinician may add other anticonvulsants which 
are inducers of drug metabolism and may result in 
toxicity without control of seizures. The combination 
may fail to control the seizures, but may result in side 
effects of drowsiness (1) and/ or hyperactivity, also. 
For example, diphenylhydantoin (DPH) at 5 
mg/ kg/ day would result in a stable blood level of the 
drug (2); however, an occasional patient on the same 
dosage may represent marked blood accumulation of 
the drug and toxicity (3), while others on the same 
dosage may reveal very low drug levels and poor 
TABLE 2 
Dosage, Therapeutic Drug Levels, Indications, and Side Effects of Routinely Used Anticonvulsants 
TD 50 Safety Serum Level• 
Average Daily Dose (Toxicity) Range Therapeutic Skin Rash Hyper-
Indications (ED 50) (mg/ kg) (TD/ ED) Range Leukopenia activity 
DPH 
(Dilan tin®) F, G, S 5 mg/ kg (0.3 g/ sqM) 20 4 10- 20 µg/ ml ± ± 
Phenobarbital 
(Luminal®) F, G, P, C, S 1.5 mg/ kg (0.1 g/ sqM) 4.5 3 10-50 µg/ ml ± +++ 
Primidone 
(Mysoline®) L, G 10 mg/ kg (0.6 g/ sqM) 140 14 4- 12 µg/ ml ± + 
Ethosuximide 
(Zarontin®) p 20 mg/ kg (1.2 g/ sqM) 150 10 40-100 µg/ ml + + 
Methsuximide 
(Celontin®) P, C 10 mg/ kg (0.6 g/ sqM) 15 1.5 2-7.5 µg/ ml ++ + 
Trimethadione 
(Tridione®) p 20 mg/ kg (l.2 g/ sqM) 25 1.2 100-1000 µg/ ml +++ + 
Diazepam 
(Valium®) S, P 2-10 mg IV repeated 30 10 150-550 ng/ ml ++ 
dose 
Clonazepam• S, P, C 0.3 mg/ kg 6 20 20- 70 ng/ ml +++ 
Acetazolamide 
(Diamox®) P, PMS 500-750 mg/ day 200 18 10- 75 µg/ ml 
Carbamazepine• 400 mg (children)/ day 
(Tegretol®) L, G 1200 mg (adults)/ day 23 1.5 4-6 µg/ ml ± + 
ACTH Infantile spasms 40-80 u 
ED-Effective dose g/ sqM- gram per square body meter 
C-Complex (myoclonic akinetic, focal and gen., "petit mal variant" ) TD-toxic dose 
F-Focal seizure ± -Rare 
G-Generalized + -Infrequent 
L-Limbic (Temporal lobe, etc.) + +-Occasional 
P-Petit mal +++-Not uncommon 
PMS-Premenstrual seizures • -Use as anticonvulsan t experimental 
S-Status epilepticus :j:-Gross guidelines 
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TABLE 3 
Measurement of Blood Levels of Anticonvulsants 
l. Patient reliability 
2. Undermedication and overmedication 
(typical and atypical toxicity; acute and chronic toxicity) 
3. Drug interaction 
4. Seizure aggravation by anticonvulsants 
5. Neurologic deterioration due to drugs vs other causes 
6. Use of anticonvulsants in hepatic or nephritic patients 
seizure control (4). Notwithstanding this variability 
in individual patients, the clinician may become 
frustrated with the patient's lack of response to treat-
ment. Without further inquiry as to the cause of this 
lack of response, the clinician may add sub-
therapeutic doses of other drug inducers. The com-
bination is apt to fail. 
The combination of the following inducers of 
drug metabolism should be avoided: I) phenobarbital 
and antipyrine; 2) phenobarbital and butazones; 3) 
phenobarbital and diphenylhydantoin (DPH); 4) 
phenobarbital and gyrseofulvin; 5) chlordiazepoxide 
and Coumadin®. 
Drug interaction is variable from case to case; 
however, high anticonvulsant levels are achieved of 
each drug, if the metabolic inducers are not given 
simultaneously (5). If in some cases a combination of 
drugs seems to be more effective, it is most likely that 
subtherapeutic doses of each agent have been used to 
begin with. This is especially true in combining 
phenobarbital and DPH. 
The combination of phenobarbital and DPH is 
in vogue. While in occasional patients such a com-
bination may be more rewarding than the individual 
use of phenobarbital or DPH, _in our study of 182 
patients suffering from focal as well as gen-
eralized seizures (Table 4), patients responded bet-
ter to phenobarbital or DPH alone than to the 
combination of the two drugs. When the patients 
were randomly divided into three groups, the group 
receiving DPH and phenobarbital in combination 
had more tendency to suffer from side effects of 
drowsiness and ataxia, and therapeutic levels of the 
anticonvulsants could not be achieved in most cases 
without the complications of undesired side effects. 
The patients who received single anticonvulsants had 
a higher level of serum anticonvulsants with fewer 
side effects of drowsiness, poor appetite, and 
hyperactivity. The patients in the combination group 
had more rapid control of seizure disorder from the 
start, but did not fare as well in the long-term follow-
up. This was blamed on the fact that the patients on 
combination therapy did not follow the treatment 
schedule as religiously as the patients in other groups 
because of the side effects. The patients receiving in-
dividual anticonvulsants had a delay of two-to-five 
days in complete control of their seizures, but had 
better control of seizure disorder when followed for a 
period of over two years (Table 4). 
Drug toxicity can be enhanced by the use of hor-
mones such as salt-retaining hormones or by the use 
of psychotherapeutic drugs such as phenothiazines. It 
is a well-known fact that phenothiazines can exacer-
bate seizures in some patients; this is especially true in 
patients suffering from limbic system originated 
seizures. This does not, however, contraindicate the 
use of phenothiazines in the epileptic patients. The 
use of some phenothiazine drugs may be absolutely 
necessary to control the emotional problems which 
TABLE 4 
DPH 
5.0 mg/ kg/ day 
Phenobarbital 
1.5 mg/ kg/day 
Combination 
Treatment of Focal and Generalized Seizures in 182 Randomly Distributed Patients 
Age Range 6-37 Years with a Two-Year Follow-up 
No. of Mean Blood Mean Blood 
Patients DPH (µg/ ml) Phenobarbital (µg/ ml) 
61 11 
51 12.3 
62 6.2 7.1 
Therapeutic Failures 
in Two Years 
13 (21.3%) 
16 (27.1 %) 
24 (38.6%) 
(Reproduced by permission of the American Academy of Pediatrics, Inc., and the author, from H. Hooshma nd, " Toxic Effects of An-
ticonvulsants: General Principles," Pediatrics 53:553, 1974.) 
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Fig. IA-Frequent, partial , complex seizures in a three-year-old 
boy diagnosed as "petit mal" without success. 
may be more incapacitating than the seizures 
themselves. Among the phenothiazines, however, the 
epileptogenic effect is variable. For example, chlor-
promazine (Thorazine®) is a much stronger epilep-
togenic agent than thioridazine (Mellaril®); the use of 
the latter drug is more strongly preferred of the two. 
Drug Specificity for the Disease. Whereas in 
therapeutic doses, anticonvulsants have in common 
the characteristic of raising the threshold of the 
seizure discharge, clinical experience has revealed 
that some of the anticonvulsants are more useful for 
specific forms of seizures. The review study by 
Coatsworth (6) has demonstrated that ethosuximide 
is more effective in the treatment of petit mal. 
Trimethadione is Jess effective in petit mal and is not 
effective in treatment of generalized convulsive 
seizures. Primidone is more helpful in the treatment 
of limbic (psychomotor) seizures and is not effective 
in petit mal seizures. If these guidelines are used, the 
medical treatment will be more successful (Table 2). 
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Fig. I 8-Methsuximide, 300 mg per day, stopped the seizures. 
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Fig. 2-Temporal lobe seizures in a 12-year-old boy misdiagnosed 
as "petit ma!." 
It should be kept in mind that an anticonvulsant 
may be very effective experimentally for a specific 
form of seizure, but it may have a narrow safety 
range measured by toxic dose compared to effective 
dose (7) (Table 2). The toxic side effects will limit the 
usefulness of such an anticonvulsant. This is true for 
trimethadione and phenacemide. Phenacemide, an 
anticonvulsant tried for treatment of temporal lobe 
seizures, is so toxic that its use is unwarranted ( 6). 
The Nature of the Disease for Which the Drug 
is Used. Therapeutic failure may be the result of in-
correct diagnosis such as the treatment of hysterical 
seizures with anticonvulsants. Other examples may 
include treatment of psychosensory seizures 
originating from the temporal lobe, misdiagnosed as 
petit mal, with medications for petit mal seizure or 
treatment of complex infantile seizures as "petit mal" 
seizures ( Figs. I, 2). 
Electroencephalography (EEG) can be a 
priceless tool in confirming the diagnosis. One cannot 
always rely on clinical expertise and judgment in 
diagnosis of seizure disorder; EEG must be used as a 
guideline for accurate diagnosis and treatment. 
Accurate diagnosis of etiologic factors in seizure 
disorder is most important in the treatment of 
neonatal seizures. More than half of these neonatal 
seizures may be caused by correctable factors such as 
calcium, magnesium, glucose, or pyridoxine 
metabolism disturbance (8). If instead of correcting 
these metabolic disturbances, anticonvulsants in 
large doses are used, the infant can easily be born 
toxic. 
The problem of the "breakthrough effect" can 
play a significant role in drug toxicity . This problem 
refers to the phenomenon of the loss of control of 
seizures despite adequate therapeutic blood levels of 
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anticonvulsants after a few months or years of 
successful treatment. Some anticonvulsants are more 
apt to develop this problem. These include 
acetazolamide (Diamox®), nitrazepam (Mogadon®), 
and, to a lesser extent, diazepam (Valium®) and 
clonazepam (Clonopin®). 
In our experience, the breakthrough effect may 
also be related to the etiologic factors. In rare cases of 
slow-growing gliomas with temporal or frontal lobe 
seizures, the breakthrough effect may herald the 
presence of the tumor years before the tumor can be 
visualized by contrast studies. 
The Mode and Frequency of Medication. The 
route and the frequency of administration of anticon-
vulsants plays a role in efficacy and toxicity. The 
frequency of administration should be approximately 
equal to the half-life of the drug (which is quite 
different from one drug to another). 
Diphenylhydantoin ( DPH). The approximate 
half-life of DPH in man ranges from 4-50 hours ac-
cording to various studies. The mean figure is 22 
hours. Unfortunately, all patients do not fall in the 
mean rate of plasma haif-life. As a result, single-dose 
administration of DPH can cause fluctuations of the 
drug level in the blood in a small number of patients 
causing confusion in treatment. This method, which 
apparently can be quite effective in adults (9), can 
cause some complication in children. In our ex-
perience, a single-dose administration of DPH can be 
irritative to the stomach, causing nausea and 
vomiting . There is no need, however, of dividing the 
dosage of DPH to more than two times per day. This 
drug should never be given intramuscularly (IM), but 
can be administered intravenously or by mouth; IM 
use causes necrosis of muscle and DPH is not 
transferred to the blood from the muscle in any 
significant therapeutic dose. DPH should not be mixed 
with other IV fluids because it is strongly alkaline. 
Long-term administration of over 7 mg/ kg of 
D PH causes lethargy, drowsiness, diplopia, confu-
sion, and ataxia; ataxia and nystagmus are crude 
signs of toxicity . Rarely, hyperactivity, poor school 
performance, psychosis , hallucinations, and de-
lusions may result. Hirsutism, seen in three-fourths 
of all patients taking DPH, is annoying but not 
serious. Gum hypertrophy is also frequently seen and 
can become so severe as to necessitate excision. 
Morbilliform rash may occur in 2% of patients; 
in these cases, DPH will have to be discontinued. 
Even though some patients can later be restarted on 
the drug, this is a risky practice. The rare com-
plications of blood dyscrasia and hepatitis definitely 
necessitate the permanent discontinuation of all 
hydantoins. 
A common benign side effect of DPH is 
lymphadenopathy. We have seen this to be mis-
diagnosed as lymphoma or lymphosarcoma. Lupus 
erythematosus (LE) is a rare complication which 
clears up after the discontinuation of DPH. The fami-
ly history is positive for LE in one-fifth of these 
patients. Another rare complication of DPH therapy 
is a mild megaloblastic anemia which can be cor-
rected with 0.1 mg folic acid daily. 
Phenobarbital. This anticonvulsant has a half-life 
of three-to-six days in man. As a result, a single daily 
dose should be efficient and effective. This single dose 
is best given at bedtime. 
The main side effect of this drug is drowsiness 
and/or aggravation of preexisting hyperactivity. 
This side effect can be effectively overcome by the ad-
dition of methylphenidate (Ritalin®), 10-30 mg in 
divided doses in the morning and at noon. A 
scarlatiniform rash may develop in 2% of patients. 
This necessitates discontinuation of the drug as does 
allergic erythematosus rash . 
Primidone ( Mysoline®). This drug has a plasma 
half-life of 4-19 hours in man with a mean of eight 
hours. It should not be given as a single dose, and 
preferably should be given every four-to-eight hours; 
tolerance to this drug develops slowly. 
Diazepam (Valium®). This drug is effective 
mainly as an anticonvulsant for the control of status 
epilepticus. It should be given in IV form in frequent 
doses . The half-life of this drug is not more than three 
Fig . 3-M anning ( 16) depth electrode. (Right) The depth electrode 
with six exposure points 5-10 mm apart. (Left) The electrodes seen 
in the middle fossa and anterior fossa of the skull. Arrows show 
points of exposure. 
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TABLE 5 
Cases of Intractable Seizures Excluded After Adjustment 
of Standard Rx• 
hours. As a result, frequent injections should be given 
until the seizure is under control. Diazepam should 
not be given IM or by mouth for the treatment of 
status epilepticus; neither should it be mixed with 
other IV medications; it is most incompatible with 
most other IV fluids . This incompatibility manifests 
itself in the form of venous blood coagulation and 
pulmonary embolus, which may have been the major 
factor in blaming this drug for the rare complications 
of respiratory arrest and death that are due to ben-
zodiazepines . 
Undermedication 
Drug interaction 
Drug toxicity 
Wrong diagnosis and Rx: 
petit mal vs limbic seizures** 
petit mal vs complex seizures*** 
hyperventilation syndrome 
conversion reaction 
1 hypoglycemia, 1 lead poisoning 
and 1 congenital heart disease 
Total 
6 
4 
4 
5 
1 
2 
3 
26 
• Of the 70 patients referred for intractable seizure, 26 
were satisfactorily treated after correction of diagnosis or 
adjustment of medication. 
Clonazepam. This is an effective anticonvulsant 
in the treatment of petit mal as well as complex minor 
motor seizures (10, I I}. Its half-life is five-to-six hours 
and it should be given by mouth every six hours . The 
major side effects are drowsiness (when given in toxic 
doses) and aggravation of hyperactivity . The 
hyperactivity can be corrected by treatment with 
methylphenidate (Ritalin®). 
** One case treated successfully with primidone alone, 
three cases with carbamazepine. 
*** All five responded favorably to methsuximide. 
Trimethadione. Because of the high tendency for 
toxicity in the form of skin rash, blood dyscrasias, as 
well as hemeralopia, and because the diones are not 
as effective anticonvulsants as succinimides (6), we 
TABLE 6 
Results of Treatment with Clonazepam in 44 Cases of Uncontrollable Seizures 
Type of Seizures 
Petit inal (absence) 
Photic sensitive 
Petit mal status (absence-
continuing) 
Sylvian 
Myoclonic 
Temporal lobe (psycho-
motor, psychosensory) 
Focal cortical 
A kinetic 
Complex (akinetic and 
myoclonic) 
Infantile spasm 
S & W-spike and waves 
Number of Cases 
1 
5 
7 
4 
JO 
7 
2 
EEG 
Gen. S & W 
Photoconvulsive 
Cont. S & W 
Mid-temporal S 
S & W plus frontal or 
temporal S 
Temporal S 
Follow-up EEG* 
Infrequent or no S & W; 
focal S 2 cases; slow back-
ground 3 cases 
Normal 
Slow background 
No S & W 
Less frequent S 
No change 
Slightly less frequent S 
Focal S (motor 3, Occip. I) No change 
S & W, poly S 8:j: plus 
frontal 3 temporal S 2 
hemispheric I 
Focal or gen. multiple 
spikes 
Hypsarrhythmia 
± 
± 
No change 
* Low voltage fast activity was invariably present 
•• 4+ excellent control , - 3+ over 75%, 2+ over 50%, + over 25% decrease or se izures , - no change 
*** ± temporary effect 
:j: Simultaneous EEG anomalies were common 
t Expired (meningitis) 
Results of Rx** 
++++ 3 cases 
± 2 cases 
++++ 
++++ 
+ + ++ 
+ ++ 3 cases 
± 2 cases 
++++ 4 cases 
± *** 3 cases 
+ + 3 cases 
± I caset 
+++ 6 cases 
+ + 2 cases 
± 2 cases 
± 6 cases 
++ I case 
- 2 cases 
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TABLE 7 
Results of Surgical (Ablation) Therapy in Eight Intractable Seizure Patients 
with a Two-to-Eight Year Follow-up 
X-Ray Age at Onset Age at Seizure Control* 
Seizure Fingings of Seizures Surgery Procedure Pathology After 2-7 Years 
Psychomotor Neg 8 yrs 14 yrs temporal glioma Ill ++ ** 
lobectomy 
Psychomotor Neg 9 yrs 15 yrs temporal oligodendro- +++ 
lobectomy glioma 
A kinetic Neg 11 yrs 17 yrs temporal no lesion +++ 
lobectomy 
A kinetic Neg 9 yrs 21 yrs temporal gliosis +++ + 
lobectomy 
Akihetic & Neg 2 yrs 6 yrs frontal lobe AV malformation ++++ 
adversive section 
Akinetic & Neg 12 yrs 22 yrs frontal lobe gliotic cyst ++++ 
grand ma! section 
Complex (akinetic, Hemiatrophy Birth 11 yrs Hemi- atrophy ++++ 
focal , gen.) spherectomy 
Grand mal R. occip. l yr 19 yrs Removal of gliosis ±t 
cyst cyst 
* 4 + excellent control, -3+ over 75%, 2+ over 50%, +over 25% decrease of seizures, - No change 
•• 4 years postop, post Ro-Rx, and post chemo-Rx 
t Died of E. coli meningitis 13 months postop 
have abandoned the use of this drug altogether. The 
usual dose in children with petit ntal is 300-900 mg/ -
day in two-to-three doses. 
Succinimides. At present, ethosuximide (Zaron-
tin®) is the drug of choice for petit mal seizures (6). It 
can aggravate generalized convulsive episodes in 
akinetic and temporal lobe seizure patients (12). 
Because of its long half-life, once- or twice-daily 
doses should be sufficient. It is metabolized as quickly 
in children as in adults. 
Methsuximide (Celontin®). In our experience, 
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Fig. 4-EEG of 14-yeat-old boy suffering from psychosensory 
seizures with concomitant fluttering of eyes. Note 3/ sec S&W 
followed by a left temporal spike transient. Poor response to 
ethosuximide treatment. 
this has been a very useful drug in the treatment of 
difficult to control (akinetic, myoclonic, etc.) seizures. 
One daily dose seems to be sufficient. It has more 
tendency for toxic side effects than does ethosuximide 
(Table 2) . Phenylsuccimide, a bi product of this drug, 
has a long half-life and can cause deep cont a ( 13). 
Carbamazepine ( Tegretol® ). Because of fluctua-
tion in blood levels, this drug should be administered 
three-to-four times daily. Blood levels of over 7 
µg / ml may result in ataxia, nausea, diplopia, 
dysarthria, and drowsiness, all dose-related (Table 2). 
TABLE 8 
Outcome of 70 Cases of Difficult Seizure Control with 
Two-to-Eight-Year Follow-up 
Management Patients Successful Rx 
Drug adjustment, 
misdiagnosis 26 23 
Clonazepam 44* 27 
Surgery [8]* 6 
Total 70 56 
Failures-14 cases 
(20%)** 
• The surgical cases were from the clonazepam failure group. 
** The failure rate was descreased from 100% to 20%. 
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TABLE 9 
Results of Medical and Surgical Treatment in 32 Patients 
Suffering from Akinetic Seizures• 
Lennox syndrome 
(age at onset birth-
5 yrs, average IQ 78) 
Complex Akinetic 
(age of onset 1-12 
yrs, average IQ 82) 
and Myoclonic 
Late Onset Akinetic 
(age of onset 5-13 
Patients 
7 
18 
yrs, average IQ 89) 7 
Total 32 
Intractable 
5 
6 
II 
* Note the relationship of patients' age to the prognostic 
response to therapy-the later the age of onset of the 
disease, the better the prognosis. 
Rare serious, allergic-type complications of blood 
dyscrasia, hepatitis, and skin rash may necessitate 
discontinuation of this drug (14); however, this drug 
can be quite safe and effective in the treatment of 
seizure disorders in children ( 15). 
Adrenocorticotrophin (ACTH). This is the drug 
of choice in infantile spasm. Although it can cause 
cushingoid features, this side effect is worth coping 
with. Every-other-day dose decreases this side effect. 
Management of Intractable Seizures. The follow-
ing is our experience with the management of intrac-
table seizures. 
Material and Method. Seventy intractable partial 
seizures were studied and followed for two-to-eight 
years. Patients who demonstrated the evidence of 
brain tumor or arteriovenous (AV) malformation on 
contrast studies were excluded from this study. The 
70 patients were evaluated for medical or surgical 
treatment. Age range was 2-34 years with an average 
of 14 years. The majority of patients were in 
childhood and teen-age groups. Thirty-eight were 
female, 32 were male. 
The depth electrode studies were done on the 
patients who had failed to respond to medical treat-
ment, and regardless of the type of generalized EEG 
discharges, showed focal spikes in their ictal, interic-
tal, or postictal EEG recordings. Manning (16) depth 
electrode was used. This is a fine depth electrode, 
thinner than other types, which can be inserted with 
little risk of trauma (Fig. 3); its six exposure points, 
5-10 mm apart, facilitate recording several points in 
depth. 
The depth studies were performed immediately 
after contrast studies, psychological tests, as well as 
an intra-arterial amobarbital test for diagnosis of 
cerebral dominance. The ventricular air remaining 
from the .air encephalogram was an important guide 
in locating the position of the depth electrodes. The 
depth electrode studies consisted of the study of the 
suspicious focal discharge as well as symmetrical 
depth electrodes positioned in temporal lobes, frontal 
lobes, and thalamic nuclei . The temporal lobe elec-
trodes were inserted from the posterior temporal 
region, advancing towards the amygdaloid nucleus 
with the tip of the electrodes resting adjacent to this 
nucleus (Fig. 3). This method would provide a record-
ing from surface to depth, from posterior to anterior 
aspects of the temporal lobes, and would facilitate 
localization of the abnormal discharges. An average 
of ten days-to-two weeks of recordings were done and 
an attempt was made to record an ictus on depth elec-
trode recording of all patients with the help of all-
night EEG recordings or EEG telemetry recordings. 
Results. Twenty of the patients were helped by 
adjustment of standard medical treatment (Table 5). 
Six patients were found to have been misdiagnosed. 
This group consisted of one patient with lead poison-
ing, one with hypoglycemia, and one patient with 
congenital heart disease. 
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Fig. 5-Six-year-old girl suffering from intractable seizures. Sur-
face EEG recording shows slow S&W. EEG returned to normal 
after removal of a right mesial frontal A Y formation. 
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The remaining 44 patients were tried on a ben-
zodiazepine-clonazepam (Table 6). This drug was 
most effective in petit ma!, petit ma! status, and 
photosensitive seizures. It was less effective in com-
plex seizures and infantile spasm (hypsarrhythmia). 
Of the 27 patients who failed to respond to 
clonazepam therapy, 15 underwent depth electrode 
studies. Of these 15 patients, eight eventually had sur-
gical treatment. These eight patients were selected 
after the depth electrode studies revealed that the 
epileptogenic focus was the source of the patients' 
clinical seizures and was amenable to surgical treat-
ment (Table 7). 
Despite the fact that repeated angiography and 
air encephalography performed in intervals as far 
apart as three-to-six years were negative before 
operation, with the help of depth electrodes, lesions 
such as tumors and AV malformation were found at 
the site of epileptogenic focus (Table 7). The end 
result was a drop of failure rate from 100% before the 
study to 20% at the completion of this study 
(Table 8). 
Discussion. The clinical and surface EEG 
diagnoses are not always accurate. The interictal sur-
face EEG findings do not necessarily correlate with 
the region of the epileptogenic focus, and may not be 
localizing in even half of the partial, adversive, or 
controversive seizures (17, 18). Simultaneous depth 
and surface recordings in patients with petit ma! 
epilepsy reveal inconclusive data regarding the site of 
origin of both the spike and slow wave discharges 
(19-21). 
Experimentally in the monkey, the electrical and 
behavioral characteristics of petit ma! epilepsy have 
been demonstrated by the production of bilateral cor-
tical epileptogenic foci (22). It has been shown that 
the focal cortical paroxysmal discharge has a tend-
ency for subcortical propagation before maturation 
and a tendency for cortical propagation after matura-
tion (23). A synchronized EEG discharge is not 
necessarily synonymous with subcortical origin. A 
cortical focus can give rise to similar seizure 
manifestations (29). In occasional cases, the suppres-
sion of the generalized 3/ sec spike and wave (S & W) 
discharges by medication may help demonstrate the 
cortical epileptogenic focus (I 0). The diagnosis of 
petit ma! does not necessarily point to a subcortical 
origin for the generalized discharges, and occasion-
ally, a limbic system focus may mimic the petit ma! 
attacks (Fig. 4). The limbic system has been 
demonstrated to extend to subcortical structures as 
well (30). Even in the cases of "typical petit ma!," the 
generalized S & W on EEG may be accompanied by 
complex behavior and automatism which may be en-
vironmentally influenced (31, 32). They may be ac-
companied by increased or decreased postural tone of 
the body (31, 32). The above may explain the com-
plexity of the subject partial seizures and the problem 
of misdiagnosis or incorrect treatment. 
A large number of patients in this study (Tables 
6, 7) suffered from akinetic seizures. This form of 
seizure (33-35) may be accompanied by slow S & W 
discharges on EEG-the "petit mal variant" (36, 37). 
The akinetic and atonic seizures seem to form a syn-
drome variable in etiologies as well as in EEG find-
ings. The "Lennox syndrome" (37), a name which 
has been used synonymously for these seizures, is 
characterized by I) age of onset, usually below six 
years of age; 2) complex seizure manifestations, such 
as akinetic and myoclonic seizures; 3) retardation; 4) 
resistance to treatment; and 5) generalized slow S & W 
discharges plus other abnormalities in three-fourths of 
cases (38, 39). Whereas this syndrome comprises the 
majority of akinetic seizures in young children who 
are also retarded, it does not encompass the entire 
spectrum of akinetic seizures. 
When the akinetic seizures occur in the older age 
patients, or in patients who do not have other aspects 
of Lennox syndrome (such as retardation), the 
prognosis seems to be more favorable. This is 
reflected clearly in our study of 32 akinetic seizure 
patients (Table 9). The EEG findings, usually that of 
slow S & W discharges in Lennox syndrome, may 
demonstrate focal discharges in older age patients 
(40-44). Our depth electrode studies confirm cortical 
origin of the epileptogenic focus in some of these 
patients (Figs . 5, 6; Table 7). 
Depth electrode studies may be very helpful in 
care of seizure patients if the following minimal 
criteria are met: I) the use of the thinnest possible 
depth electrodes; 2) a suggestion of focal discharges on 
surface recording; 3) the confirmation of cerebral 
dominance by intra-arterial amobarbital test before 
any surgical procedure; and 4) the recording of the ic-
tal event from the surgically resectable epileptogenic 
focus. 
In our experience (Table 7), repeated negative 
contrast studies over the years do not rule out the 
possibility of brain tumor or AV malformation as the 
cause of seizure disorder (Fig. 5). Crandall (45), in his 
experience with depth electrode studies in seven in-
tractable partial seizures, noted one patient suffering 
/ 
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Fig. 6A-Eleven-year-old girl with intractable seizures and left-
sided hemiplegia since birth. Surface EEG recording shows 
bilateral multispikes. 
from corpus callosum astrocytoma who suffered 
from attacks of becoming rigid and falling backward 
as well as psychomotor seizures. This patient, along 
with another patient who had a small meningeal 
angioma, had negative contrast studies. Page et al. 
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Fig. 68-Electrocortiography (ECoG) before and after 
hemispherectomy. Right-postoperative surface EEG shows no 
more spikes. Patient is seizure free. No more need for anticonvul-
sant therapy. 
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Fig. ?-Comparison of the results of therapy among seizure 
patients referred to the seizure control clinic. As noted, un-
dermedication and overmedication comprise the majority of 
failure cases. 
(46), while underlining the importance of brain tumor 
as the causative factor in rare cases of childhood 
seizure disorders, emphasized the fact that a change 
of seizure pattern in EEG or in behavioral school per-
formance should make one suspicious of the 
possibility of brain tumor as the causative factor. 
It is concluded that with adjustment of treat-
ment, accurate diagnostic work-up, trial of new an-
ticonvulsants, and surgical therapy for partial 
seizures, the failure rate may drop from 100% to 20% 
(Table 8, Fig. 7). 
Prevention of Seizure Disorders. The knowledge 
about seizure disorders has advanced to the point of 
considering prevention. 
Prenatal Prevention. Maternal toxoplasmosis, 
syphilis, and cytomegalovirus infections should be 
diagnosed and aggressively treated. Maternal hygiene 
and nutrition play a role in the size of the child. The 
low birth-weight children a re at risk for neonatal 
seizure disorders. 
Neonatal and Infantile Prevention. Early 
diagnosis and effective treatment of neonatal 
meningitis can prevent the late complications of in-
tractable seizures. Immunization, especially for 
measles and mumps, should be strongly encouraged. 
Febrile seizures should be aggressively treated and 
prevented by antipyretic and anticonvulsant 
(phenobarbital) therapy to prevent mesial and tem-
poral anoxic damage and subsequent late-onset tem-
poral lobe seizures. 
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Prevention of Head Injury . Prevention of head 
injury by the use of seat-belts in the car, and by en-
couraging the schools to avoid building cement floors 
under swings in the playground can be helpful. 
The Role of Eugenics. The role of eugenics is 
limited to such diseases as Huntington's chorea, 
phenylketonuria, and mucopolysaccharidosis; how-
ever, intermarriage among families with high risk 
seizure disorders may be discouraged. 
Psychosocial Aspects. This is one area where un-
fortunately no recent progress has been made. The 
general public still has a medieval attitude toward 
epileptics. More education for the public as well as 
for health officials is needed. 
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